1000+
Abcam employees worldwide
140+
PhD's within the company
12
Locations
globally
130
Countries delivered to worldwide
64%
Global researchers use Abcam products

Welcome to Abcam Investor
Relations

Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.

Our mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Our ambition is to become the most influential life science company for researchers worldwide.

We continue to identify the biological pathways of greatest interest to our consumers and continuously strive to provide products of the highest quality with increased specificity, reproducibility and sensitivity.  At the same time, through investment and acquisition, we are expanding into new markets, identifying new technologies and applications while moving into new geographic regions, thereby driving sustainable growth.

Headquartered in Cambridge, UK, we employ over 1000 people across twelve locations serving researchers in more than 130 countries.

About Abcam

Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research.

Read more +

Abcam Products

As an innovator in reagents and tools, Abcam offers highly validated binders and assays to address important targets in critical biological pathways.

Read more +

Investor Information

Abcam is listed on the AIM market of the London Stock Exchange under the ticker ABC, and our investors' centre includes a range of information on our company, including our news, financial reports and investor contacts

Read more +

Abcam News

We provide updates on our commercial and financial progress through regular press releases which can be accessed through the Company's media centre.

Read more +

We aspire to be the most influential life science company for researchers worldwide

Alan Hirzel
Chief Executive Officer

Abcam
Highlighted News

Continued strong sales growth in the first half, ahead of underlying market rates

6th Mar 2018

Revenue growth of 9.8% (11.2% constant currency1) Full year constant currency revenue growth guidance increased to c.11%, including the impact of the Spring Bioscience licence agreement signed in January 2018 FINANCIAL HIGHLIGHTS Total revenue growth of 9.8% on a reported...

Read more +

Abcam Signs Exclusive License Agreement with Roche

22nd Jan 2018

22 January 2018 The product portfolio of Spring Bioscience Corporation to be licensed to Abcam for research use only (RUO) applications The portfolio includes 243 recombinant rabbit monoclonal antibodies Abcam (AIM: ABC), a global leader in the supply of life...

Read more +

Double-digit earnings growth enabling investment for sustained future growth

11th Sep 2017

Abcam plc (“Abcam” or “the Company”, AIM: ABC), a global leader in the supply of life science research tools, is pleased to announce its preliminary results for the year ended 30 June 2017. FINANCIAL HIGHLIGHTS Total revenue increased 26.5% on...

Read more +